Ibrance (palbociclib) | Friends of Cancer Research

You are here

Ibrance (palbociclib)

Sponsor: 
Pfizer Inc.
Indication: 
In combination with an aromatase inhibitor, and in combination with fulvestrant, for treatment of male patients with advanced or metastatic breast cancer
Category: 
Year: 
2017
FDA Status: 
FDA Approval
Approval Date: 
Apr 4th
Approval Year: 
2019